project id: TCGA-PRAD; case submitter id: TCGA-KC-A7FA; source center: 23; state: released; a260 a280 ratio: 1.9; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.18; rna integrity number: 7.7; age at index: 63; days to birth: -23208; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1950; age at diagnosis: 23208; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N0; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 598.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 146; initial weight: 120.0; sample id: a7086ff4-1aa3-4d27-bf97-987269b2ebe6; sample submitter id: TCGA-KC-A7FA-01A; portion id: c29def0e-3ea2-4371-ae76-f9b250fd5805; portion submitter id: TCGA-KC-A7FA-01A-21; slide id: 564a5f1c-94c1-4ae4-b9a8-bbe6ce548944; slide submitter id: TCGA-KC-A7FA-01A-02-TSB; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 15.0; percent stromal cells: 0.0; percent tumor cells: 85.0; percent tumor nuclei: 75.0; section location: TOP;